Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib

BACKGROUND: Objective response of advanced adrenocortical carcinoma (ACC) to mitotane and cytotoxic chemotherapy regimen is only ~20% and early tumor progression is frequent. Previous clinical trials with oral multikinase inhibitors were negative, which has been attributed in part to inadvertent dru...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Endocrinol Metab
Asıl Yazarlar: Kroiss, Matthias, Megerle, Felix, Kurlbaum, Max, Zimmermann, Sebastian, Wendler, Julia, Jimenez, Camilo, Lapa, Constantin, Quinkler, Marcus, Scherf-Clavel, Oliver, Habra, Mouhammed Amir, Fassnacht, Martin
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2020
Konular:
Clinical Research Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8204945/
https://ncbi.nlm.nih.gov/pubmed/31900481
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/clinem/dgz318
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller